Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 6Active not recruiting 3Terminated 2Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Renal Cell 20Sarcoma 4Neuroendocrine Tumors 4Neoplasms 4Carcinoma, Medullary 4Carcinoma, Hepatocellular 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Kidney Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Melanoma 2Lung Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Neuroendocrine 2Carcinoma 2Adenocarcinoma, Follicular 2Wilms Tumor 1Urologic Neoplasms 1

Interventions

Nivolumab 8belzutifan 7pembrolizumab 6Ipilimumab 5cabozantinib 3Surveys and Questionnaires 3lenvatinib 2Radiosurgery 2Paclitaxel 2Everolimus 2Carboplatin 2pazopanib 1palbociclib 1liposomal doxorubicin 1guadecitabine 1fludarabine phosphate 1endothelial PAS domain-containing protein 1 1durvalumab 1cemiplimab 1atezolizumab 1aldesleukin 1X-Rays 1Technetium Tc 99m Sestamibi 1Taxes 1Sunitinib 1Spermine Synthase 1Social Determinants of Health 1Single Photon Emission Computed Tomography Computed Tomography 1Radiotherapy 1Radionuclide Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Kidney Neoplasms × cabozantinib × Clear all
NCT04322955 2026-06-05

Cyto-KIK

Columbia University

Phase 2 Active not recruiting
38 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03634540 2024-12-20

MK-6482-003

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting
118 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT02293980 2024-06-17

MK-3795-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting
110 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡